Partnering Opportunities

Safe and effective delivery is clearly a challenge for the many types of active agent nucleic acids in development by the pharma/biotech industry.

Lamellar is keen to explore potential opportunities for collaboration with organisations seeking improved delivery of their active agent nucleic acid as well as companies capable of taking our lead products through clinical development.